SlideShare a Scribd company logo
1
By
The spike glycoproteins create corona, bind and fuse with host cell membranes
 Human coronaviruses were first identified in the mid-1960s, are so
named because of the crown-like appearance of their virus particles
when seen under an electron microscope (corona, meaning crown).
 Coronaviruses are a diverse group of viruses that infect and cause
disease in humans and other animals.
 Coronaviruses are large, enveloped, positive-strand RNA viruses that
be divided into 4 genera: alpha, beta, delta, and gamma, of which alpha
and beta CoVs are known to infect humans.
 Four HCoVs (HCoV 229E, NL63, OC43, and HKU1) are endemic globally
and account for 10% to 30% of upper respiratory tract infections in
adults.
Coronavirus Infections—More Than Just the Common Cold
 Human coronaviruses (HCoVs) have long been considered inconsequential
pathogens, causing the “common cold” in otherwise healthy people.
 Until recently, HCoVs received relatively little attention due to their mild
phenotypes in humans.
 However, in the 21st century, 2 highly pathogenic HCoVs—severe acute
respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory
syndrome coronavirus (MERS-CoV) — emerged from animal reservoirs to
cause global epidemics with alarming morbidity and mortality.
 In December 2019, yet another pathogenic HCoV, 2019 novel coronavirus
(2019-nCoV), was recognized in Wuhan, China, and has caused serious
illness and death.
 Coronaviruses are ecologically diverse with the greatest variety seen in
bats, suggesting that they are the reservoirs for many of these viruses.
 Peridomestic mammals may serve as intermediate hosts, facilitating
recombination and mutation events with expansion of genetic diversity.
 Coronaviruses are a family of viruses causing infection in humans and a
variety of animals including birds and mammals such as camels, cats
and bats.
 When animal coronaviruses evolve, infect people and then spread
between humans, it can lead to outbreaks such as what happened with
MERS-CoV and SARS.
 Several known coronaviruses are circulating in animals that have not
yet infected humans.
 To date, seven coronaviruses have been shown to also infect and cause
illness in humans.
 People around the world commonly get infected with human
coronaviruses 229E, NL63, OC43, and HKU1.
 Sometimes coronaviruses that infect animals can evolve and make
people sick and become a new human coronavirus.
 Three recent examples of this are 2019-nCoV, SARS-CoV, and MERS-CoV.
In the case of SARS, the virus jumped from bats to civet cats before
gaining the ability to infect humans. In the case of MERS, camels
served as the intermediate host.
SARS Coronavirus
Background
 The current outbreak of the 2019-nCoV virus started in Wuhan City,
Hubei Province, China.
 While the first cases were reported as early as December 8, 2019, the
outbreak gained global attention on December 31, 2019, when the
World Health Organization (WHO) was alerted to “several cases of
pneumonia” by an unknown virus.
 The new virus was soon identified as a novel corona virus and named
2019-nCOV.
 The 2019-nCoV identified in China is a new strain of coronavirus that
has not been previously identified in humans.
 It belongs to the family of viruses that include the common cold and
viruses such as SARS and MERS.
Cluster of pneumonia cases linked to seafood market in Wuhan
 In the case of 2019-nCoV outbreak, reports state that most of the first group
of patients hospitalized were workers or customers at a local seafood
wholesale market which also sold processed meats and live consumable
animals .
 The study of the genetic code of 2019-nCoV reveals that the new virus is most
closely related to two bat SARS-like coronavirus samples from China
 "Bats being the native host of the Wuhan CoV (coronavirus) would be the
logical and convenient reasoning, though it remains likely there was
intermediate host(s) in the transmission cascade from bats to humans,“
 When the researchers performed a more detailed bioinformatics analysis
of the sequence of 2019-nCoV, it suggests that this coronavirus might
come from snakes (snake is the most probable wildlife animal reservoir).
From bats to snakes
 Snakes often hunt for bats in wild. Reports indicate that snakes were
sold in the local seafood market in Wuhan, raising the possibility that
the 2019-nCoV might have jumped from the host species — bats — to
snakes and then to humans at the beginning of this coronavirus
outbreak
 The novel corona virus, is likely originated in a wet market in the city of
Wuhan.
 The markets put shoppers, vendors, and live and dead animals in close
proximity, which raises the risk of a disease outbreak, since corona
viruses are zoonotic diseases (meaning they can jump from animals to
people).
Craze for exotic meat
 The food market where the deadly virus surfaced offered a range of
exotic wildlife for sale, including live foxes, crocodiles, wolf puppies,
giant salamanders, snakes, rats, peacocks, porcupines, camel meat
other game.
 Authorities believe the virus likely came from "wild animals at the
seafood market" .
 Many exotic species are still widely consumed in China or other Asian
countries where they are considered a delicacy - like the civet or some
rats or bats - or for purported health benefits unproven by science.
 Severe Acute Respiratory Syndrome, or SARS, was linked to Chinese
consumption of civet meat.
 The 2019-nCoV outbreak is another reminder that people should limit
the consumption of wild animals to prevent zoonotic infections.
 First SARS, now the Wuhan coronavirus. Here’s why China should ban its
wildlife trade forever.
 Both coronaviruses are linked to live animal markets, where sick,
injured and dying animals are sold as exotic foods but end up
transmitting disease.
 For too long, wildlife traders have been allowed to hide behind empty
claims of medicine or conservation. It’s time to ban the unsavoury trade
permanently.
The Huanan Seafood Wholesale Market in Wuhan, closed on January 1, is thought to be ground
zero in the spread of the deadly coronavirus named 2019-nCoV.
It's being passed between humans
 The WHO said that it believed an animal source was the "primary source"
of the outbreak, and Wuhan authorities identified a seafood market as
the centre of the epidemic.
 There was evidence the virus is now passing from person to person, without
any contact with the now-closed market.
The Arkansas Democrat-Gazette
Chinese lock down 8 cities to curb deadly virus's spread
As of 26 Jan,2020
As of 28 Jan ,2020
As of 29 Jan ,2020
 TheWHO defines a global emergency — formally, a Public Health Emergency
of International Concern — as “an extraordinary event which is determined
to constitute a public health risk to other States through the international
spread of disease and to potentially require a coordinated international
response.”
 Despite the emergency declaration, the WHO is not recommending any
restrictions on travel or trade at this time.
 Countries should implement evidence-based public health policies, combat
misinformation, share data, and work together to stop the spread of the virus
US State Department issues highest level alert: ‘Do Not Travel to Ch
As of 3 Feb 2020
 Human to human transmission has been confirmed. Researchers
and public health officials determine how contagious a virus is by
calculating a reproduction number, or R0.
 The R0 is the average number of other people that one infected
person will infect, in a completely non-immune population.
 The World Health Organization said that the preliminary R0
(reproduction number) estimate is 1.4 to 2.5, meaning that every
person infected could infect between 1.4 and 2.5 people.
 Person-to-person spread of 2019-nCoV is occurring. Chinese officials
report that sustained person-to-person spread in the community is
occurring in China.
 Person-to-person spread in the United States has not yet been
detected, but it’s likely to occur to some extent.
 "An initial first impression is that this is significantly milder than
SARS," "That's reassuring. On the other hand, it may be more
transmissible than SARS, at least in the community setting.“
 For now, 2019-nCoV appears to have a lower fatality rate than the
SARS virus, but it is certainly appears to be spreading quicker.
How does it compare with SARS or MERS?
 MERS was first identified in Saudi Arabia in 2012, and around 34% of people
reported as infected with the virus have died (858 of 2494 cases). Its R0 is less
than one.
 The SARS outbreak of 2002-03led to 8098 identified cases and 774 deaths
(9.6%). It has an R0 of 2-5.7
 The good news is that the data to date suggest that this virus may have a lower
mortality than SARS
Incubation Period of 2019-nCoV
 1-14 days after exposure (Most cases remain asymptomatic during this
period)
 The virus has been noted to have a long incubation period of 1-14 days,
with patients remaining asymptomatic until the occurrence of the
disease.
 China has confirmed human-to-human transmission, and said the virus is
infectious during its 1-14 day incubation period -- in other words, before
the first symptoms appear.
23
433
400
Risk Factors of 2019-nCoV
From the data collected by the CDC, the persons at risk are:`
1. Elderly persons above the age of 50 persons with underlying diseases
like diabetes, Parkinson’s disease, cardiovascular diseases.
2. Demographically, it can also be stated that the persons living in China
around Wahun town are most at risk, especially those working&
shopping from Animal markets within the localities; and persons
traveling into and out of Wahun.
3. Hospital-acquired infection- Health care workers caring for patients with
the 2019-nCoV
The epidemiological and clinical criteria that should prompt laboratory
testing of suspected cases of 2019-nCoV. The criteria include:
Epidemiological criteria Clinical criteria
Any person with travel-history to Wuhan City,
China in the 14 days before the onset of illness
Any person with clinical symptoms compatible
with severe acute respiratory infection seeking
healthcare or admitted to hospital with clinical
or radiological evidence of pneumonia
(or) Any person being in close contact with a
laboratory-confirmed case of 2019-nCoV in the
14 days before the onset of illness
(or) Any person with fever or recent history of
fever (>=38°C) and acute respiratory infection
(sudden onset of respiratory infection with one
or more of the following symptoms: shortness of
breath, cough or sore throat)
Criteria to initiate testing for 2019-nCoV
 Any person fulfilling the criteria for a suspect case should be tested for
2019-nCoV. The laboratory test should be initiated immediately.
 it is likely that respiratory specimens collected early after symptoms’
onset would yield higher virus concentrations.
 Rapid collection and testing of appropriate specimens from suspected
cases is a priority.
Samples to be collected
1. Respiratory samples (nasopharyngeal and oropharyngeal swab in
ambulatory patients and sputum (if produced) and/or
endotracheal aspirate or bronchoalveolar lavage in patients with more severe
respiratory disease).
2. Serum for serological testing, acute sample and convalescent sample (this
is additional to respiratory materials and can support the identification of the
true agent, once serologic assay is available).
 Recommendations for specimen collection Lower respiratory specimens likely
have a higher diagnostic value than upper respiratory tract specimens for
detecting 2019-nCoV infection.
 If patients do not have signs or symptoms of lower respiratory tract disease
or if specimen collection for lower respiratory tract disease is clinically
indicated but the collection is not possible, upper respiratory tract
specimens such as a nasopharyngeal aspirate or combined nasopharyngeal and
and oropharyngeal swabs should be collected.
 Patients that meet the case definition for suspected 2019- nCoV
should be screened for the virus with RT-PCR.
 If case management requires, screen also for other common causes of
respiratory illness according to local guidelines.
 As coinfections can occur, all patients that meet the case definition
should be tested for 2019-nCoV regardless of whether a conventional
respiratory pathogen is found.
 If initial testing is negative in a patient who is strongly suspected to have
2019-nCoV infection, the patient should be resampled and specimens
collected from multiple respiratory tract sites (sputum, endotracheal
aspirate).
 A single negative test result, particularly if this is from an upper respiratory
tract specimen, does not exclude infection.
 Repeat sampling and testing, lower respiratory specimen is strongly
recommended in severe or progressive disease.
Remarks:
 Use appropriate PPE for specimen collection (droplet and contact
precautions for URT specimens; airborne precautions for LRT specimens).
 When collecting URT samples, use viral swabs (sterile Dacron or rayon,
not cotton) and viral transport media. Do not sample the nostrils or
tonsils.
 In a patient with suspected novel coronavirus, especially with pneumonia
or severe illness, a single URT sample does not exclude the diagnosis, and
additional URT and LRT samples are recommended.
Remarks:
 LRT (vs. URT) samples are more likely to be positive and for a longer
period.
 Clinicians may elect to collect only LRT samples when these are readily
available (for example, in mechanically ventilated patients).
 Sputum induction should be avoided due to increased risk of
increasing aerosol transmission.
Remarks:
 Dual infections with other respiratory viral infections have been found in
SARS and MERS cases.
 Both URT and LRT specimens can tested for other respiratory viruses,
such as influenza A and B (including zoonotic influenza A), respiratory
syncytial virus, parainfluenza viruses, ect.
 LRT specimens can also be tested for bacterial pathogens, including
Legionella pneumophila.
 In hospitalized patients with confirmed nCoV infection, repeat URT and
LRT samples should be collected to demonstrate viral clearance.
 The frequency of specimen collection will depend on local circumstances
but should be at least every 2 to 4 days until there are two consecutive
negative results (both URT and LRT samples if both are collected) in a
clinically recovered patient at least 24 hours apart.
Clinical management of severe acute respiratory infection when
novel coronavirus (2019-nCoV) infection is suspected
1. Triage: recognize and sort all patients with SARI associated with 2019-
nCoV infection at first point of contact with health care system (such as
the emergency department).
 Consider 2019-nCOV as a possible etiology of SARI under certain
conditions
 Triage patients and start emergency treatments based based on disease
severity.
Remarks
 2019-nCoV infection may present with mild, moderate, or severe illness; the
latter includes severe pneumonia, ARDS,sepsis and septic shock.
 Early recognition of suspected patients allows for timely initiation of IPC
 Early identification of those with severe manifestations allows for immediate
optimized supportive care treatments and safe, rapid admission (or referral)
to intensive care unit according to institutional or national protocols.
2. Immediate implementation of appropriate IPC measures
 IPC is a critical and integral part of clinical management of patients and
should be initiated at the point of entry of the patient to hospital (typically
the Emergency Department).
 Standard precautions should always be routinely applied in all areas of
health care facilities.
 Standard precautions include hand hygiene; use of PPE to avoid direct
contact with patients’ blood, body fluids,secretions (including respiratory
secretions) and non-intact skin.
 Standard precautions also include prevention of needle-stick or sharps
safe waste management; cleaning and disinfection of equipment; and
cleaning of the environment.
137
139
140
144
150
3. Early supportive therapy and monitoring
Give supplemental oxygen therapy immediately to patients with SARI and
respiratory distress, hypoxaemia, or shock.
Remarks: Initiate oxygen therapy at 5 L/min and titrate flow rates to reach target
SpO2 ≥90% in non-pregnant adults and SpO2 ≥92-95 % in pregnant patients.
 Children with emergency signs (obstructed or absent breathing, severe
respiratory distress, central cyanosis, shock, coma or convulsions) should receive
oxygen therapy during resuscitation to target SpO2 ≥94%; otherwise, the target
SpO2 is ≥90%.
 All areas where patients with SARI are cared for should be equipped with pulse
oximeters, functioning oxygen systems and disposable, single-use, oxygen-
delivering interfaces (nasal cannula, simple face mask, and mask with reservoir
4. Give empiric antimicrobials to treat all likely pathogens
causing SARI.
 Give antimicrobials within one hour of initial patient assessment for patients
with sepsis
 Empiric antibiotic treatment should be based on the clinical diagnosis
(community-acquired pneumonia, health care-associated pneumonia [if
infection was acquired in healthcare setting], or sepsis), local epidemiology
susceptibility data, and treatment guidelines.
 Empiric therapy includes a neuraminidase inhibitor for treatment of
influenza when there is local circulation or other risk factors, including
travel history or exposure to animal influenza viruses.
 Empiric therapy should be de-escalated on the basis of microbiology results
and clinical judgment.
Remarks
 Patients with SARI should be treated cautiously with intravenous fluids,
because aggressive fluid resuscitation may worsen oxygenation, especially
in settings where there is limited availability of mechanical ventilation.
 Do not routinely give systemic corticosteroids for treatment of viral
pneumonia or ARDS outside of clinical trials unless they are indicated for
another reason.
 Closely monitor patients with SARI for signs of clinical deterioration, such
as rapidly progressive respiratory failure and sepsis,and apply supportive
care interventions immediately.
 Remarks: Application of timely, effective, and safe supportive therapies is
the cornerstone of therapy for patients that develop severe
manifestations of 2019-nCoV.
 Understand the patient’s co-morbid condition(s) to tailor the management
of critical illness;
 Remarks: During intensive care management of SARI, determine which
chronic therapies should be continued and which therapies should be
stopped temporarily.
 There is no current evidence from RCTs to recommend any
specific anti-nCoV treatment for patients with suspected or
confirmed 2019-nCoV infection.
Special considerations for pregnant patients
 Pregnant women with suspected or confirmed 2019-nCoV infection
should be treated with supportive therapies as described above, taking
into account the physiologic adaptations of pregnancy
 Emergency delivery and pregnancy termination decisions are challenging
and based on many factors: gestational age, maternal condition, and
fetal stability. Consultations with obstetric, neonatal, and intensive care
specialists (depending on the condition of the mother) are essential.
184
193
A militia member uses a digital thermometer to take a driver's temperature at
a checkpoint at a highway toll gate in Wuhan, China, January 23, 2020.
A worker monitors display screens for infrared thermometers as
part of traveler screenings at Hankou Railway Station in Wuhan,
China, January 21, 2020.
200
Panic is our enemy
Knowledge is our friend
Preparation is our best line of
defence
“The only thing more difficult than planning for an
emergency is having to explain why you didn’t.”
Be Proactive NOT Reactive!!!!
Final Messages!
203
Thank you

More Related Content

What's hot

Kuwait flu vaccine booklet for workshop
Kuwait flu vaccine booklet for workshopKuwait flu vaccine booklet for workshop
Kuwait flu vaccine booklet for workshop
Ashraf ElAdawy
 
Clinical case Management Of Severe Acute Respiratory Infection SARI
Clinical case Management Of Severe Acute Respiratory Infection SARIClinical case Management Of Severe Acute Respiratory Infection SARI
Clinical case Management Of Severe Acute Respiratory Infection SARI
Ashraf ElAdawy
 
Influenza
InfluenzaInfluenza
Everything we need to know about COVID-19
Everything we need to know about COVID-19Everything we need to know about COVID-19
Everything we need to know about COVID-19
PrincessExtra
 
Trivalent Inacivated Seasonal Influenza Vaccine(TIV)
 Trivalent Inacivated Seasonal Influenza Vaccine(TIV)  Trivalent Inacivated Seasonal Influenza Vaccine(TIV)
Trivalent Inacivated Seasonal Influenza Vaccine(TIV)
Ashraf ElAdawy
 
Influenza a emergency prepardness for healthcare facilities
Influenza a emergency prepardness for healthcare facilitiesInfluenza a emergency prepardness for healthcare facilities
Influenza a emergency prepardness for healthcare facilities
Moustapha Ramadan
 
Corona Virus Awareness by, Er. Swapnil V. Kaware
Corona Virus Awareness by, Er. Swapnil V. KawareCorona Virus Awareness by, Er. Swapnil V. Kaware
Corona Virus Awareness by, Er. Swapnil V. Kaware
Prof. Swapnil V. Kaware
 
Corona virus
Corona virusCorona virus
Corona virus
SumitBhatia69
 
Corona
Corona Corona
Corona
Priya
 
Kuwait influenza case management guidelines for 2nd flu workshop 2016
Kuwait influenza case management guidelines for 2nd flu workshop 2016Kuwait influenza case management guidelines for 2nd flu workshop 2016
Kuwait influenza case management guidelines for 2nd flu workshop 2016
Ashraf ElAdawy
 
Seasonal influenza vaccines
Seasonal influenza vaccines Seasonal influenza vaccines
Seasonal influenza vaccines
Ashraf ElAdawy
 
Control and prevention_of_influenza
Control and prevention_of_influenzaControl and prevention_of_influenza
Control and prevention_of_influenzaChandan N
 
Influenza facts and prevention
Influenza facts and preventionInfluenza facts and prevention
Influenza facts and prevention
Moustapha Ramadan
 
Covid 19
Covid 19 Covid 19
Covid 19
Waheed Shouman
 
Corona virus (covid 19) by Gaurav Jain
Corona virus (covid 19) by Gaurav JainCorona virus (covid 19) by Gaurav Jain
Corona virus (covid 19) by Gaurav Jain
Gaurav Jain
 
CORONA VIRUS
CORONA VIRUSCORONA VIRUS
Influenza
InfluenzaInfluenza
Influenza
KULDEEP VYAS
 
Pandemic Flu
Pandemic FluPandemic Flu
Pandemic Flu
AtlantaSafetyCouncil
 

What's hot (20)

Kuwait flu vaccine booklet for workshop
Kuwait flu vaccine booklet for workshopKuwait flu vaccine booklet for workshop
Kuwait flu vaccine booklet for workshop
 
Clinical case Management Of Severe Acute Respiratory Infection SARI
Clinical case Management Of Severe Acute Respiratory Infection SARIClinical case Management Of Severe Acute Respiratory Infection SARI
Clinical case Management Of Severe Acute Respiratory Infection SARI
 
Influenza
InfluenzaInfluenza
Influenza
 
Influenza8p
Influenza8pInfluenza8p
Influenza8p
 
Everything we need to know about COVID-19
Everything we need to know about COVID-19Everything we need to know about COVID-19
Everything we need to know about COVID-19
 
Trivalent Inacivated Seasonal Influenza Vaccine(TIV)
 Trivalent Inacivated Seasonal Influenza Vaccine(TIV)  Trivalent Inacivated Seasonal Influenza Vaccine(TIV)
Trivalent Inacivated Seasonal Influenza Vaccine(TIV)
 
Influenza a emergency prepardness for healthcare facilities
Influenza a emergency prepardness for healthcare facilitiesInfluenza a emergency prepardness for healthcare facilities
Influenza a emergency prepardness for healthcare facilities
 
Corona Virus Awareness by, Er. Swapnil V. Kaware
Corona Virus Awareness by, Er. Swapnil V. KawareCorona Virus Awareness by, Er. Swapnil V. Kaware
Corona Virus Awareness by, Er. Swapnil V. Kaware
 
Corona virus
Corona virusCorona virus
Corona virus
 
Corona
Corona Corona
Corona
 
Kuwait influenza case management guidelines for 2nd flu workshop 2016
Kuwait influenza case management guidelines for 2nd flu workshop 2016Kuwait influenza case management guidelines for 2nd flu workshop 2016
Kuwait influenza case management guidelines for 2nd flu workshop 2016
 
Seasonal influenza vaccines
Seasonal influenza vaccines Seasonal influenza vaccines
Seasonal influenza vaccines
 
Control and prevention_of_influenza
Control and prevention_of_influenzaControl and prevention_of_influenza
Control and prevention_of_influenza
 
Influenza facts and prevention
Influenza facts and preventionInfluenza facts and prevention
Influenza facts and prevention
 
Covid 19
Covid 19 Covid 19
Covid 19
 
Corona virus (covid 19) by Gaurav Jain
Corona virus (covid 19) by Gaurav JainCorona virus (covid 19) by Gaurav Jain
Corona virus (covid 19) by Gaurav Jain
 
CORONA VIRUS
CORONA VIRUSCORONA VIRUS
CORONA VIRUS
 
Influenza In Long Term Care
Influenza In Long Term CareInfluenza In Long Term Care
Influenza In Long Term Care
 
Influenza
InfluenzaInfluenza
Influenza
 
Pandemic Flu
Pandemic FluPandemic Flu
Pandemic Flu
 

Similar to Novel corona virus 2019 (2019 - nCov)

Epidemiology and outbreak status of 2019 Novel coronavirus (2019-nCoV)
Epidemiology and outbreak status of 2019 Novel coronavirus (2019-nCoV)Epidemiology and outbreak status of 2019 Novel coronavirus (2019-nCoV)
Epidemiology and outbreak status of 2019 Novel coronavirus (2019-nCoV)
Nusrat Sultana
 
2019-nCoV presentation
2019-nCoV presentation2019-nCoV presentation
2019-nCoV presentation
Nusrat Sultana
 
Some quick facts and numbers on Coronavirus (COVID-19)
Some quick facts and numbers on Coronavirus (COVID-19) Some quick facts and numbers on Coronavirus (COVID-19)
Some quick facts and numbers on Coronavirus (COVID-19)
Slide Marvels
 
Novel corona virus (n cov 2019)
Novel corona virus (n cov  2019)Novel corona virus (n cov  2019)
Novel corona virus (n cov 2019)
Barnali Singha Bithi
 
Covid19- a brief introduction
Covid19- a brief introductionCovid19- a brief introduction
Covid19- a brief introduction
rakeshkrishna33
 
Abstract Covid-19
Abstract Covid-19Abstract Covid-19
Abstract Covid-19
haseebgg
 
COVID-19 (Coronavirus Disease 2019)
COVID-19 (Coronavirus Disease 2019)COVID-19 (Coronavirus Disease 2019)
COVID-19 (Coronavirus Disease 2019)
TAUHIDUR RAHAMAN MONDAL
 
Coronavirus: All you need to know about symptoms and risks
Coronavirus: All you need to know about symptoms and risksCoronavirus: All you need to know about symptoms and risks
Coronavirus: All you need to know about symptoms and risks
ahmiz2428
 
COVID-19 presentation by Sadi
COVID-19 presentation by SadiCOVID-19 presentation by Sadi
COVID-19 presentation by Sadi
SoFia119
 
Top 10 viruses
Top 10 virusesTop 10 viruses
Top 10 viruses
ramanjaneyachariVemu
 
Introduction to coronavirus diseases
Introduction to coronavirus diseasesIntroduction to coronavirus diseases
Introduction to coronavirus diseases
ruchirabalvir
 
Travel related infectious disease 2.pptx
Travel related infectious disease 2.pptxTravel related infectious disease 2.pptx
Travel related infectious disease 2.pptx
GovindRankawat1
 
PAPER ENGLISH FOR UAS - Rafaeldo Cassydi
PAPER ENGLISH FOR UAS - Rafaeldo CassydiPAPER ENGLISH FOR UAS - Rafaeldo Cassydi
PAPER ENGLISH FOR UAS - Rafaeldo Cassydi
FaelXC
 
Novel coronavirus outbreak
Novel coronavirus outbreakNovel coronavirus outbreak
Novel coronavirus outbreak
Syed Kamrul Hasan
 
J.jare.2020.03.005
J.jare.2020.03.005J.jare.2020.03.005
J.jare.2020.03.005
ThalyCruz
 
2 years into the pandemic, what have we learned?
2 years into the pandemic, what have we learned?2 years into the pandemic, what have we learned?
2 years into the pandemic, what have we learned?
nareshkumargovindan2
 
SOURCE DISPLAY.docx
SOURCE DISPLAY.docxSOURCE DISPLAY.docx
SOURCE DISPLAY.docx
nareshkumargovindan2
 
SOURCE DISPLAY.docx
SOURCE DISPLAY.docxSOURCE DISPLAY.docx
SOURCE DISPLAY.docx
nareshkumargovindan2
 
COVID 19
COVID 19COVID 19
COVID 19
ijtsrd
 

Similar to Novel corona virus 2019 (2019 - nCov) (20)

Epidemiology and outbreak status of 2019 Novel coronavirus (2019-nCoV)
Epidemiology and outbreak status of 2019 Novel coronavirus (2019-nCoV)Epidemiology and outbreak status of 2019 Novel coronavirus (2019-nCoV)
Epidemiology and outbreak status of 2019 Novel coronavirus (2019-nCoV)
 
2019-nCoV presentation
2019-nCoV presentation2019-nCoV presentation
2019-nCoV presentation
 
Some quick facts and numbers on Coronavirus (COVID-19)
Some quick facts and numbers on Coronavirus (COVID-19) Some quick facts and numbers on Coronavirus (COVID-19)
Some quick facts and numbers on Coronavirus (COVID-19)
 
Novel corona virus (n cov 2019)
Novel corona virus (n cov  2019)Novel corona virus (n cov  2019)
Novel corona virus (n cov 2019)
 
Covid19- a brief introduction
Covid19- a brief introductionCovid19- a brief introduction
Covid19- a brief introduction
 
Abstract Covid-19
Abstract Covid-19Abstract Covid-19
Abstract Covid-19
 
COVID-19 (Coronavirus Disease 2019)
COVID-19 (Coronavirus Disease 2019)COVID-19 (Coronavirus Disease 2019)
COVID-19 (Coronavirus Disease 2019)
 
Coronavirus: All you need to know about symptoms and risks
Coronavirus: All you need to know about symptoms and risksCoronavirus: All you need to know about symptoms and risks
Coronavirus: All you need to know about symptoms and risks
 
COVID-19 presentation by Sadi
COVID-19 presentation by SadiCOVID-19 presentation by Sadi
COVID-19 presentation by Sadi
 
Top 10 viruses
Top 10 virusesTop 10 viruses
Top 10 viruses
 
Introduction to coronavirus diseases
Introduction to coronavirus diseasesIntroduction to coronavirus diseases
Introduction to coronavirus diseases
 
Travel related infectious disease 2.pptx
Travel related infectious disease 2.pptxTravel related infectious disease 2.pptx
Travel related infectious disease 2.pptx
 
PAPER ENGLISH FOR UAS - Rafaeldo Cassydi
PAPER ENGLISH FOR UAS - Rafaeldo CassydiPAPER ENGLISH FOR UAS - Rafaeldo Cassydi
PAPER ENGLISH FOR UAS - Rafaeldo Cassydi
 
Novel coronavirus outbreak
Novel coronavirus outbreakNovel coronavirus outbreak
Novel coronavirus outbreak
 
Sars 2
Sars 2Sars 2
Sars 2
 
J.jare.2020.03.005
J.jare.2020.03.005J.jare.2020.03.005
J.jare.2020.03.005
 
2 years into the pandemic, what have we learned?
2 years into the pandemic, what have we learned?2 years into the pandemic, what have we learned?
2 years into the pandemic, what have we learned?
 
SOURCE DISPLAY.docx
SOURCE DISPLAY.docxSOURCE DISPLAY.docx
SOURCE DISPLAY.docx
 
SOURCE DISPLAY.docx
SOURCE DISPLAY.docxSOURCE DISPLAY.docx
SOURCE DISPLAY.docx
 
COVID 19
COVID 19COVID 19
COVID 19
 

More from Ashraf ElAdawy

How to get your taste and smell back after covid-19?
How to get your taste and smell back after covid-19?How to get your taste and smell back after covid-19?
How to get your taste and smell back after covid-19?
Ashraf ElAdawy
 
Quadrivalent influenza vaccine
Quadrivalent influenza vaccineQuadrivalent influenza vaccine
Quadrivalent influenza vaccine
Ashraf ElAdawy
 
Brain fog, insomnia, and stress: Coping after COVID
Brain fog, insomnia, and stress: Coping after COVIDBrain fog, insomnia, and stress: Coping after COVID
Brain fog, insomnia, and stress: Coping after COVID
Ashraf ElAdawy
 
How to manage fatigue after covid-19
How to manage fatigue after covid-19How to manage fatigue after covid-19
How to manage fatigue after covid-19
Ashraf ElAdawy
 
Managing breathlessness with long covid
Managing breathlessness with long covidManaging breathlessness with long covid
Managing breathlessness with long covid
Ashraf ElAdawy
 
Post COVID Syndrome
Post COVID SyndromePost COVID Syndrome
Post COVID Syndrome
Ashraf ElAdawy
 
COVID-19 : A look at possible future Scenarios?
COVID-19 : A look at possible future Scenarios?  COVID-19 : A look at possible future Scenarios?
COVID-19 : A look at possible future Scenarios?
Ashraf ElAdawy
 
Asthma, COPD with COVID-19: What should HCPs need to know?
Asthma, COPD with COVID-19: What should HCPs need to know?Asthma, COPD with COVID-19: What should HCPs need to know?
Asthma, COPD with COVID-19: What should HCPs need to know?
Ashraf ElAdawy
 
Novel coronavirus (COVID-2019) What we need to know?
Novel coronavirus (COVID-2019) What we need to know?Novel coronavirus (COVID-2019) What we need to know?
Novel coronavirus (COVID-2019) What we need to know?
Ashraf ElAdawy
 
فيروس الكورونا المستجد 2019
فيروس الكورونا المستجد 2019فيروس الكورونا المستجد 2019
فيروس الكورونا المستجد 2019
Ashraf ElAdawy
 
Asthma Inhaler Techniques In Children
 Asthma Inhaler Techniques In Children Asthma Inhaler Techniques In Children
Asthma Inhaler Techniques In Children
Ashraf ElAdawy
 
Asthma Medications in Clinical Practice - Part 2
Asthma Medications in Clinical Practice - Part 2Asthma Medications in Clinical Practice - Part 2
Asthma Medications in Clinical Practice - Part 2
Ashraf ElAdawy
 
Asthma Mangement: Time for a New Approach
Asthma Mangement: Time for a New ApproachAsthma Mangement: Time for a New Approach
Asthma Mangement: Time for a New Approach
Ashraf ElAdawy
 
Updates on pharmacological management of COPD 2020
Updates on pharmacological management of COPD 2020Updates on pharmacological management of COPD 2020
Updates on pharmacological management of COPD 2020
Ashraf ElAdawy
 
Asthma Medications in Clinical Practice - Part 1
Asthma Medications in Clinical Practice - Part 1Asthma Medications in Clinical Practice - Part 1
Asthma Medications in Clinical Practice - Part 1
Ashraf ElAdawy
 
Asthma and inhaler usage tips - part 2
Asthma and inhaler usage tips - part 2Asthma and inhaler usage tips - part 2
Asthma and inhaler usage tips - part 2
Ashraf ElAdawy
 
Pneumococcal vaccine in adults “Clinical Scenarios”
Pneumococcal vaccine in adults “Clinical Scenarios”Pneumococcal vaccine in adults “Clinical Scenarios”
Pneumococcal vaccine in adults “Clinical Scenarios”
Ashraf ElAdawy
 
Pneumococcal vaccine in adults with CKD “Clinical Scenarios”
Pneumococcal vaccine in adults with CKD “Clinical Scenarios”Pneumococcal vaccine in adults with CKD “Clinical Scenarios”
Pneumococcal vaccine in adults with CKD “Clinical Scenarios”
Ashraf ElAdawy
 
Asthma and inhaler usage tips - part 1
Asthma and inhaler usage tips - part 1Asthma and inhaler usage tips - part 1
Asthma and inhaler usage tips - part 1
Ashraf ElAdawy
 
Influenza in Children Recommendations for Prevention &Treatment
Influenza in Children Recommendations for Prevention &Treatment   Influenza in Children Recommendations for Prevention &Treatment
Influenza in Children Recommendations for Prevention &Treatment
Ashraf ElAdawy
 

More from Ashraf ElAdawy (20)

How to get your taste and smell back after covid-19?
How to get your taste and smell back after covid-19?How to get your taste and smell back after covid-19?
How to get your taste and smell back after covid-19?
 
Quadrivalent influenza vaccine
Quadrivalent influenza vaccineQuadrivalent influenza vaccine
Quadrivalent influenza vaccine
 
Brain fog, insomnia, and stress: Coping after COVID
Brain fog, insomnia, and stress: Coping after COVIDBrain fog, insomnia, and stress: Coping after COVID
Brain fog, insomnia, and stress: Coping after COVID
 
How to manage fatigue after covid-19
How to manage fatigue after covid-19How to manage fatigue after covid-19
How to manage fatigue after covid-19
 
Managing breathlessness with long covid
Managing breathlessness with long covidManaging breathlessness with long covid
Managing breathlessness with long covid
 
Post COVID Syndrome
Post COVID SyndromePost COVID Syndrome
Post COVID Syndrome
 
COVID-19 : A look at possible future Scenarios?
COVID-19 : A look at possible future Scenarios?  COVID-19 : A look at possible future Scenarios?
COVID-19 : A look at possible future Scenarios?
 
Asthma, COPD with COVID-19: What should HCPs need to know?
Asthma, COPD with COVID-19: What should HCPs need to know?Asthma, COPD with COVID-19: What should HCPs need to know?
Asthma, COPD with COVID-19: What should HCPs need to know?
 
Novel coronavirus (COVID-2019) What we need to know?
Novel coronavirus (COVID-2019) What we need to know?Novel coronavirus (COVID-2019) What we need to know?
Novel coronavirus (COVID-2019) What we need to know?
 
فيروس الكورونا المستجد 2019
فيروس الكورونا المستجد 2019فيروس الكورونا المستجد 2019
فيروس الكورونا المستجد 2019
 
Asthma Inhaler Techniques In Children
 Asthma Inhaler Techniques In Children Asthma Inhaler Techniques In Children
Asthma Inhaler Techniques In Children
 
Asthma Medications in Clinical Practice - Part 2
Asthma Medications in Clinical Practice - Part 2Asthma Medications in Clinical Practice - Part 2
Asthma Medications in Clinical Practice - Part 2
 
Asthma Mangement: Time for a New Approach
Asthma Mangement: Time for a New ApproachAsthma Mangement: Time for a New Approach
Asthma Mangement: Time for a New Approach
 
Updates on pharmacological management of COPD 2020
Updates on pharmacological management of COPD 2020Updates on pharmacological management of COPD 2020
Updates on pharmacological management of COPD 2020
 
Asthma Medications in Clinical Practice - Part 1
Asthma Medications in Clinical Practice - Part 1Asthma Medications in Clinical Practice - Part 1
Asthma Medications in Clinical Practice - Part 1
 
Asthma and inhaler usage tips - part 2
Asthma and inhaler usage tips - part 2Asthma and inhaler usage tips - part 2
Asthma and inhaler usage tips - part 2
 
Pneumococcal vaccine in adults “Clinical Scenarios”
Pneumococcal vaccine in adults “Clinical Scenarios”Pneumococcal vaccine in adults “Clinical Scenarios”
Pneumococcal vaccine in adults “Clinical Scenarios”
 
Pneumococcal vaccine in adults with CKD “Clinical Scenarios”
Pneumococcal vaccine in adults with CKD “Clinical Scenarios”Pneumococcal vaccine in adults with CKD “Clinical Scenarios”
Pneumococcal vaccine in adults with CKD “Clinical Scenarios”
 
Asthma and inhaler usage tips - part 1
Asthma and inhaler usage tips - part 1Asthma and inhaler usage tips - part 1
Asthma and inhaler usage tips - part 1
 
Influenza in Children Recommendations for Prevention &Treatment
Influenza in Children Recommendations for Prevention &Treatment   Influenza in Children Recommendations for Prevention &Treatment
Influenza in Children Recommendations for Prevention &Treatment
 

Recently uploaded

The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 

Recently uploaded (20)

The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 

Novel corona virus 2019 (2019 - nCov)

  • 1. 1
  • 2.
  • 3. By
  • 4.
  • 5.
  • 6.
  • 7.
  • 8. The spike glycoproteins create corona, bind and fuse with host cell membranes
  • 9.  Human coronaviruses were first identified in the mid-1960s, are so named because of the crown-like appearance of their virus particles when seen under an electron microscope (corona, meaning crown).  Coronaviruses are a diverse group of viruses that infect and cause disease in humans and other animals.
  • 10.  Coronaviruses are large, enveloped, positive-strand RNA viruses that be divided into 4 genera: alpha, beta, delta, and gamma, of which alpha and beta CoVs are known to infect humans.  Four HCoVs (HCoV 229E, NL63, OC43, and HKU1) are endemic globally and account for 10% to 30% of upper respiratory tract infections in adults.
  • 11. Coronavirus Infections—More Than Just the Common Cold  Human coronaviruses (HCoVs) have long been considered inconsequential pathogens, causing the “common cold” in otherwise healthy people.  Until recently, HCoVs received relatively little attention due to their mild phenotypes in humans.
  • 12.  However, in the 21st century, 2 highly pathogenic HCoVs—severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) — emerged from animal reservoirs to cause global epidemics with alarming morbidity and mortality.  In December 2019, yet another pathogenic HCoV, 2019 novel coronavirus (2019-nCoV), was recognized in Wuhan, China, and has caused serious illness and death.
  • 13.
  • 14.
  • 15.  Coronaviruses are ecologically diverse with the greatest variety seen in bats, suggesting that they are the reservoirs for many of these viruses.  Peridomestic mammals may serve as intermediate hosts, facilitating recombination and mutation events with expansion of genetic diversity.
  • 16.
  • 17.
  • 18.  Coronaviruses are a family of viruses causing infection in humans and a variety of animals including birds and mammals such as camels, cats and bats.  When animal coronaviruses evolve, infect people and then spread between humans, it can lead to outbreaks such as what happened with MERS-CoV and SARS.
  • 19.  Several known coronaviruses are circulating in animals that have not yet infected humans.  To date, seven coronaviruses have been shown to also infect and cause illness in humans.
  • 20.  People around the world commonly get infected with human coronaviruses 229E, NL63, OC43, and HKU1.  Sometimes coronaviruses that infect animals can evolve and make people sick and become a new human coronavirus.  Three recent examples of this are 2019-nCoV, SARS-CoV, and MERS-CoV.
  • 21. In the case of SARS, the virus jumped from bats to civet cats before gaining the ability to infect humans. In the case of MERS, camels served as the intermediate host.
  • 22.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32. Background  The current outbreak of the 2019-nCoV virus started in Wuhan City, Hubei Province, China.  While the first cases were reported as early as December 8, 2019, the outbreak gained global attention on December 31, 2019, when the World Health Organization (WHO) was alerted to “several cases of pneumonia” by an unknown virus.
  • 33.  The new virus was soon identified as a novel corona virus and named 2019-nCOV.  The 2019-nCoV identified in China is a new strain of coronavirus that has not been previously identified in humans.  It belongs to the family of viruses that include the common cold and viruses such as SARS and MERS.
  • 34.
  • 35.
  • 36. Cluster of pneumonia cases linked to seafood market in Wuhan
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.  In the case of 2019-nCoV outbreak, reports state that most of the first group of patients hospitalized were workers or customers at a local seafood wholesale market which also sold processed meats and live consumable animals .  The study of the genetic code of 2019-nCoV reveals that the new virus is most closely related to two bat SARS-like coronavirus samples from China
  • 49.  "Bats being the native host of the Wuhan CoV (coronavirus) would be the logical and convenient reasoning, though it remains likely there was intermediate host(s) in the transmission cascade from bats to humans,“  When the researchers performed a more detailed bioinformatics analysis of the sequence of 2019-nCoV, it suggests that this coronavirus might come from snakes (snake is the most probable wildlife animal reservoir).
  • 50. From bats to snakes  Snakes often hunt for bats in wild. Reports indicate that snakes were sold in the local seafood market in Wuhan, raising the possibility that the 2019-nCoV might have jumped from the host species — bats — to snakes and then to humans at the beginning of this coronavirus outbreak
  • 51.  The novel corona virus, is likely originated in a wet market in the city of Wuhan.  The markets put shoppers, vendors, and live and dead animals in close proximity, which raises the risk of a disease outbreak, since corona viruses are zoonotic diseases (meaning they can jump from animals to people).
  • 52.
  • 53.
  • 54. Craze for exotic meat  The food market where the deadly virus surfaced offered a range of exotic wildlife for sale, including live foxes, crocodiles, wolf puppies, giant salamanders, snakes, rats, peacocks, porcupines, camel meat other game.  Authorities believe the virus likely came from "wild animals at the seafood market" .
  • 55.  Many exotic species are still widely consumed in China or other Asian countries where they are considered a delicacy - like the civet or some rats or bats - or for purported health benefits unproven by science.  Severe Acute Respiratory Syndrome, or SARS, was linked to Chinese consumption of civet meat.  The 2019-nCoV outbreak is another reminder that people should limit the consumption of wild animals to prevent zoonotic infections.
  • 56.  First SARS, now the Wuhan coronavirus. Here’s why China should ban its wildlife trade forever.  Both coronaviruses are linked to live animal markets, where sick, injured and dying animals are sold as exotic foods but end up transmitting disease.  For too long, wildlife traders have been allowed to hide behind empty claims of medicine or conservation. It’s time to ban the unsavoury trade permanently.
  • 57.
  • 58.
  • 59.
  • 60.
  • 61.
  • 62. The Huanan Seafood Wholesale Market in Wuhan, closed on January 1, is thought to be ground zero in the spread of the deadly coronavirus named 2019-nCoV.
  • 63.
  • 64.
  • 65. It's being passed between humans  The WHO said that it believed an animal source was the "primary source" of the outbreak, and Wuhan authorities identified a seafood market as the centre of the epidemic.  There was evidence the virus is now passing from person to person, without any contact with the now-closed market.
  • 66.
  • 67.
  • 68.
  • 69.
  • 70.
  • 71.
  • 72.
  • 73. The Arkansas Democrat-Gazette Chinese lock down 8 cities to curb deadly virus's spread
  • 74.
  • 75. As of 26 Jan,2020
  • 76.
  • 77. As of 28 Jan ,2020
  • 78. As of 29 Jan ,2020
  • 79.
  • 80.
  • 81.
  • 82.
  • 83.
  • 84.  TheWHO defines a global emergency — formally, a Public Health Emergency of International Concern — as “an extraordinary event which is determined to constitute a public health risk to other States through the international spread of disease and to potentially require a coordinated international response.”  Despite the emergency declaration, the WHO is not recommending any restrictions on travel or trade at this time.  Countries should implement evidence-based public health policies, combat misinformation, share data, and work together to stop the spread of the virus
  • 85. US State Department issues highest level alert: ‘Do Not Travel to Ch
  • 86.
  • 87.
  • 88.
  • 89.
  • 90. As of 3 Feb 2020
  • 91.
  • 92.
  • 93.
  • 94.  Human to human transmission has been confirmed. Researchers and public health officials determine how contagious a virus is by calculating a reproduction number, or R0.  The R0 is the average number of other people that one infected person will infect, in a completely non-immune population.  The World Health Organization said that the preliminary R0 (reproduction number) estimate is 1.4 to 2.5, meaning that every person infected could infect between 1.4 and 2.5 people.
  • 95.
  • 96.  Person-to-person spread of 2019-nCoV is occurring. Chinese officials report that sustained person-to-person spread in the community is occurring in China.  Person-to-person spread in the United States has not yet been detected, but it’s likely to occur to some extent.
  • 97.
  • 98.
  • 99.  "An initial first impression is that this is significantly milder than SARS," "That's reassuring. On the other hand, it may be more transmissible than SARS, at least in the community setting.“  For now, 2019-nCoV appears to have a lower fatality rate than the SARS virus, but it is certainly appears to be spreading quicker.
  • 100.
  • 101. How does it compare with SARS or MERS?  MERS was first identified in Saudi Arabia in 2012, and around 34% of people reported as infected with the virus have died (858 of 2494 cases). Its R0 is less than one.  The SARS outbreak of 2002-03led to 8098 identified cases and 774 deaths (9.6%). It has an R0 of 2-5.7  The good news is that the data to date suggest that this virus may have a lower mortality than SARS
  • 102.
  • 103. Incubation Period of 2019-nCoV  1-14 days after exposure (Most cases remain asymptomatic during this period)  The virus has been noted to have a long incubation period of 1-14 days, with patients remaining asymptomatic until the occurrence of the disease.  China has confirmed human-to-human transmission, and said the virus is infectious during its 1-14 day incubation period -- in other words, before the first symptoms appear.
  • 105.
  • 106.
  • 107. Risk Factors of 2019-nCoV From the data collected by the CDC, the persons at risk are:` 1. Elderly persons above the age of 50 persons with underlying diseases like diabetes, Parkinson’s disease, cardiovascular diseases. 2. Demographically, it can also be stated that the persons living in China around Wahun town are most at risk, especially those working& shopping from Animal markets within the localities; and persons traveling into and out of Wahun. 3. Hospital-acquired infection- Health care workers caring for patients with the 2019-nCoV
  • 108.
  • 109.
  • 110.
  • 111.
  • 112.
  • 113.
  • 114. The epidemiological and clinical criteria that should prompt laboratory testing of suspected cases of 2019-nCoV. The criteria include: Epidemiological criteria Clinical criteria Any person with travel-history to Wuhan City, China in the 14 days before the onset of illness Any person with clinical symptoms compatible with severe acute respiratory infection seeking healthcare or admitted to hospital with clinical or radiological evidence of pneumonia (or) Any person being in close contact with a laboratory-confirmed case of 2019-nCoV in the 14 days before the onset of illness (or) Any person with fever or recent history of fever (>=38°C) and acute respiratory infection (sudden onset of respiratory infection with one or more of the following symptoms: shortness of breath, cough or sore throat)
  • 115.
  • 116. Criteria to initiate testing for 2019-nCoV  Any person fulfilling the criteria for a suspect case should be tested for 2019-nCoV. The laboratory test should be initiated immediately.  it is likely that respiratory specimens collected early after symptoms’ onset would yield higher virus concentrations.  Rapid collection and testing of appropriate specimens from suspected cases is a priority.
  • 117. Samples to be collected 1. Respiratory samples (nasopharyngeal and oropharyngeal swab in ambulatory patients and sputum (if produced) and/or endotracheal aspirate or bronchoalveolar lavage in patients with more severe respiratory disease). 2. Serum for serological testing, acute sample and convalescent sample (this is additional to respiratory materials and can support the identification of the true agent, once serologic assay is available).
  • 118.  Recommendations for specimen collection Lower respiratory specimens likely have a higher diagnostic value than upper respiratory tract specimens for detecting 2019-nCoV infection.  If patients do not have signs or symptoms of lower respiratory tract disease or if specimen collection for lower respiratory tract disease is clinically indicated but the collection is not possible, upper respiratory tract specimens such as a nasopharyngeal aspirate or combined nasopharyngeal and and oropharyngeal swabs should be collected.
  • 119.  Patients that meet the case definition for suspected 2019- nCoV should be screened for the virus with RT-PCR.  If case management requires, screen also for other common causes of respiratory illness according to local guidelines.  As coinfections can occur, all patients that meet the case definition should be tested for 2019-nCoV regardless of whether a conventional respiratory pathogen is found.
  • 120.  If initial testing is negative in a patient who is strongly suspected to have 2019-nCoV infection, the patient should be resampled and specimens collected from multiple respiratory tract sites (sputum, endotracheal aspirate).  A single negative test result, particularly if this is from an upper respiratory tract specimen, does not exclude infection.  Repeat sampling and testing, lower respiratory specimen is strongly recommended in severe or progressive disease.
  • 121. Remarks:  Use appropriate PPE for specimen collection (droplet and contact precautions for URT specimens; airborne precautions for LRT specimens).  When collecting URT samples, use viral swabs (sterile Dacron or rayon, not cotton) and viral transport media. Do not sample the nostrils or tonsils.  In a patient with suspected novel coronavirus, especially with pneumonia or severe illness, a single URT sample does not exclude the diagnosis, and additional URT and LRT samples are recommended.
  • 122. Remarks:  LRT (vs. URT) samples are more likely to be positive and for a longer period.  Clinicians may elect to collect only LRT samples when these are readily available (for example, in mechanically ventilated patients).  Sputum induction should be avoided due to increased risk of increasing aerosol transmission.
  • 123. Remarks:  Dual infections with other respiratory viral infections have been found in SARS and MERS cases.  Both URT and LRT specimens can tested for other respiratory viruses, such as influenza A and B (including zoonotic influenza A), respiratory syncytial virus, parainfluenza viruses, ect.  LRT specimens can also be tested for bacterial pathogens, including Legionella pneumophila.
  • 124.  In hospitalized patients with confirmed nCoV infection, repeat URT and LRT samples should be collected to demonstrate viral clearance.  The frequency of specimen collection will depend on local circumstances but should be at least every 2 to 4 days until there are two consecutive negative results (both URT and LRT samples if both are collected) in a clinically recovered patient at least 24 hours apart.
  • 125.
  • 126.
  • 127.
  • 128.
  • 129.
  • 130.
  • 131.
  • 132.
  • 133. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected 1. Triage: recognize and sort all patients with SARI associated with 2019- nCoV infection at first point of contact with health care system (such as the emergency department).  Consider 2019-nCOV as a possible etiology of SARI under certain conditions  Triage patients and start emergency treatments based based on disease severity.
  • 134. Remarks  2019-nCoV infection may present with mild, moderate, or severe illness; the latter includes severe pneumonia, ARDS,sepsis and septic shock.  Early recognition of suspected patients allows for timely initiation of IPC  Early identification of those with severe manifestations allows for immediate optimized supportive care treatments and safe, rapid admission (or referral) to intensive care unit according to institutional or national protocols.
  • 135. 2. Immediate implementation of appropriate IPC measures  IPC is a critical and integral part of clinical management of patients and should be initiated at the point of entry of the patient to hospital (typically the Emergency Department).  Standard precautions should always be routinely applied in all areas of health care facilities.  Standard precautions include hand hygiene; use of PPE to avoid direct contact with patients’ blood, body fluids,secretions (including respiratory secretions) and non-intact skin.  Standard precautions also include prevention of needle-stick or sharps safe waste management; cleaning and disinfection of equipment; and cleaning of the environment.
  • 136. 137
  • 137.
  • 138. 139
  • 139. 140
  • 140.
  • 141.
  • 142.
  • 143. 144
  • 144.
  • 145.
  • 146.
  • 147.
  • 148.
  • 149. 150
  • 150. 3. Early supportive therapy and monitoring Give supplemental oxygen therapy immediately to patients with SARI and respiratory distress, hypoxaemia, or shock. Remarks: Initiate oxygen therapy at 5 L/min and titrate flow rates to reach target SpO2 ≥90% in non-pregnant adults and SpO2 ≥92-95 % in pregnant patients.  Children with emergency signs (obstructed or absent breathing, severe respiratory distress, central cyanosis, shock, coma or convulsions) should receive oxygen therapy during resuscitation to target SpO2 ≥94%; otherwise, the target SpO2 is ≥90%.  All areas where patients with SARI are cared for should be equipped with pulse oximeters, functioning oxygen systems and disposable, single-use, oxygen- delivering interfaces (nasal cannula, simple face mask, and mask with reservoir
  • 151. 4. Give empiric antimicrobials to treat all likely pathogens causing SARI.  Give antimicrobials within one hour of initial patient assessment for patients with sepsis  Empiric antibiotic treatment should be based on the clinical diagnosis (community-acquired pneumonia, health care-associated pneumonia [if infection was acquired in healthcare setting], or sepsis), local epidemiology susceptibility data, and treatment guidelines.
  • 152.  Empiric therapy includes a neuraminidase inhibitor for treatment of influenza when there is local circulation or other risk factors, including travel history or exposure to animal influenza viruses.  Empiric therapy should be de-escalated on the basis of microbiology results and clinical judgment.
  • 153. Remarks  Patients with SARI should be treated cautiously with intravenous fluids, because aggressive fluid resuscitation may worsen oxygenation, especially in settings where there is limited availability of mechanical ventilation.  Do not routinely give systemic corticosteroids for treatment of viral pneumonia or ARDS outside of clinical trials unless they are indicated for another reason.
  • 154.  Closely monitor patients with SARI for signs of clinical deterioration, such as rapidly progressive respiratory failure and sepsis,and apply supportive care interventions immediately.  Remarks: Application of timely, effective, and safe supportive therapies is the cornerstone of therapy for patients that develop severe manifestations of 2019-nCoV.
  • 155.  Understand the patient’s co-morbid condition(s) to tailor the management of critical illness;  Remarks: During intensive care management of SARI, determine which chronic therapies should be continued and which therapies should be stopped temporarily.
  • 156.  There is no current evidence from RCTs to recommend any specific anti-nCoV treatment for patients with suspected or confirmed 2019-nCoV infection.
  • 157. Special considerations for pregnant patients  Pregnant women with suspected or confirmed 2019-nCoV infection should be treated with supportive therapies as described above, taking into account the physiologic adaptations of pregnancy  Emergency delivery and pregnancy termination decisions are challenging and based on many factors: gestational age, maternal condition, and fetal stability. Consultations with obstetric, neonatal, and intensive care specialists (depending on the condition of the mother) are essential.
  • 158.
  • 159.
  • 160.
  • 161.
  • 162.
  • 163.
  • 164.
  • 165.
  • 166.
  • 167.
  • 168.
  • 169.
  • 170.
  • 171.
  • 172.
  • 173.
  • 174.
  • 175.
  • 176.
  • 177.
  • 178.
  • 179.
  • 180.
  • 181.
  • 182.
  • 183. 184
  • 184.
  • 185.
  • 186.
  • 187.
  • 188.
  • 189.
  • 190.
  • 191.
  • 192. 193
  • 193.
  • 194. A militia member uses a digital thermometer to take a driver's temperature at a checkpoint at a highway toll gate in Wuhan, China, January 23, 2020.
  • 195.
  • 196.
  • 197. A worker monitors display screens for infrared thermometers as part of traveler screenings at Hankou Railway Station in Wuhan, China, January 21, 2020.
  • 198.
  • 199. 200
  • 200. Panic is our enemy Knowledge is our friend Preparation is our best line of defence
  • 201. “The only thing more difficult than planning for an emergency is having to explain why you didn’t.” Be Proactive NOT Reactive!!!! Final Messages!